Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grifols ADR Representing One Non-Voting Ord Shs Class B GRFS

Healthcare Biotechnology
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.


NDAQ:GRFS - Post by User

Grifols ADR Representing One Non-Voting Ord Shs Class B
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(26)
•••
Post by ZeroRisk2u533on Nov 27, 2024 11:33am
16 Views
Post# 36333660

$GRFS Drops After Rejecting Buyout, $MYNZ Rises

$GRFS Drops After Rejecting Buyout, $MYNZ Rises$GRFS (Grifols, S.A.) tumbled on Nov 27 after rejecting a €6.45B buyout from Brookfield Asset Management, calling it undervalued. The €10.50 per Class A share offer disappointed investors, sparking volatility. Meanwhile, $MYNZ surged 8% yesterday on strong volume, riding sector momentum.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities